Core Insights - In 2025, Chinese innovative pharmaceutical companies lacking funds but possessing pipelines are aligning with multinational pharmaceutical companies that have funds but lack pipelines, leading to significant licensing deals [1] - A historic moment for China's biopharmaceutical industry occurred in May 2025 when 3SBio announced a deal with Pfizer worth over $6 billion, setting a record for Chinese innovative drugs going overseas [1][3] - The surge in License-out transactions, particularly in the Antibody-Drug Conjugate (ADC) sector, indicates a growing trend of Chinese companies seeking international partnerships [1][3] Industry Trends - The ADC market in China is transitioning from "fast-following" to "best-in-class" and even "first-in-class" innovations, with a notable increase in the number of ADC projects [2][3] - In the first half of 2025, the global pharmaceutical transaction volume reached 456 deals, a 32% year-on-year increase, with China contributing nearly 50% of the total transaction value [3] - The number of innovative drug pipelines in China surged from hundreds in 2015 to 3,575 in 2024, marking a significant increase in First-in-Class drugs [3] Market Dynamics - The capital environment is shifting, with License-out transactions becoming a crucial funding source for biotech companies facing a financing winter [3][10] - Multinational pharmaceutical companies are urgently seeking external innovations to replenish their pipelines due to impending patent expirations affecting over $200 billion in market size by 2030 [3][10] - The trend of "early-stage project licensing" is prominent, with nearly 70% of License-out projects being in preclinical to Phase I stages, particularly in the ADC sector [6][8] Competitive Advantages - Chinese companies possess traditional advantages in chemistry and strong execution capabilities, allowing them to rapidly advance clinical trials and obtain data [4][10] - The combination of innovative approaches and engineering design in ADC development aligns well with the cultural and operational characteristics of Chinese enterprises [4] - The increasing recognition of Chinese companies' R&D capabilities by multinational firms is leading to greater willingness to invest in early-stage projects [7][8] Future Opportunities - Emerging targets like CDH17 and B7H3 are expected to become significant growth areas in the ADC market, with several companies already pursuing these targets [11][13] - The potential for antibody-drug conjugates (ADCs) and other conjugates (XDCs) to drive future growth is recognized, with a focus on innovative payloads and mechanisms [5][12] - The trend of expanding product portfolios to include earlier-stage projects reflects a strategic shift among multinational companies to ensure a continuous flow of new products [8][9]

为更好地对母基金在中国资本市场里所发挥的重要作用进行系统研究，发挥政府出资产业投资 基金等的资源和战略优势，加强政府对社会资本的管理和引导，促进社会资本流向创新创业型 企业和实体经济，推动中国投资行业特别是母基金行业的健康发展， "中国国际科技促进会母 基金分会"（简称"科促会母基金分会"）成立。科促会母基金分会领导班子所在机构及参会机 构共 8 2 家，科促会母基金分会于每周二更新相关机构的一周资讯。 【内容提要】 1 .这支国家级母基金又出手了 7 . 上海交易集团一行来绍考察调研 近日，江夏科投集团联合知名投资机构国投创业，共同完成对无锡智现未来科技有限公司（以 下简称 "智现未来"）的A轮投资，本轮总投资规模超亿元人民币。此次投资通过江夏区创业投 资基金直投，资金将用于进一步强化智现未来在设备监测、分析建模、工艺控制、良率改进等 方面的领先优势，重点推进生成式人工智能技术在半导体制造全流程中的应用落地和范式创 新，并助力国产半导体生态的协同优化。 8 . 国投集团所属国经环保基金公司与中国航发集团航发基金公司开展业务交流洽谈 智现未来为泛半导体制造产业提供良率、生产效率和产出的全面管理，主要产品包括经 ...